Stockscreener 앱 받기
36.37
0.28%
0.10
시장 영업 전:
36.62
0.25
+0.69%
Sarepta Therapeutics Inc 주식(SRPT)의 최신 뉴스
2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying - The Motley Fool
Sarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential - Insider Monkey
Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday - MSN
Sarepta’s Week Goes From Bad to Worse on FDA Fears, Outlook Cut - Bloomberg.com
New FDA Leadership Could Raise The Bar For Drug Approvals - Benzinga
These 3 Biotech Picks Can Combat Sarepta Losses After Unexpected Death - TheStreet Pro
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta ... - Bluefield Daily Telegraph
Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back? - Yahoo Finance
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference | SRPT Stock News - GuruFocus
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference - Business Wire
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Sarepta Therapeutics (SRPT) Faces Investment Rating Downgrade - GuruFocus
Sarepta price target lowered to $125 from $183 at Needham - Yahoo Finance
Sarepta Therapeutics (SRPT) Price Target Lowered by Wells Fargo | SRPT Stock News - GuruFocus
SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm | FinancialContent - FinancialContent
UBS Cuts Price Target on Sarepta Therapeutics to $85 From $188, Keeps Buy Rating - marketscreener.com
The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot - simplywall.st
Evercore ISI cuts Sarepta stock rating, slashes price target - Investing.com
Sarepta Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Sarepta (SRPT) Downgraded by Evercore ISI with New Price Target | SRPT Stock News - GuruFocus
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT) - Yahoo Finance
Sarepta Therapeutics: Buy Rating Maintained Amid Growth Potential and Valuation Opportunity - TipRanks
Beware of Sarepta, CRISPR Therapeutics, and More - Baystreet.ca
Long-Term Potential and Strategic Developments Drive Buy Rating for Sarepta Therapeutics Despite Short-Term Challenges - TipRanks
Sarepta Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment - insights.citeline.com
Some unshod by Prasad nod as CBER change socks stocks - BioWorld MedTech
The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low - Investor's Business Daily
Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating - Seeking Alpha
Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why - Yahoo Finance
Sarepta Therapeutics Stock Plunges on Guidance Cut. Its ‘Moneymaker’ Is Under Fire. - Barron's
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up - Benzinga
BMO Capital cuts Sarepta stock target to $120, maintains Outperform - Investing.com
Cantor Fitzgerald cuts Sarepta stock target to $81 - Investing.com
Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade (NASDAQ:SRPT) - Seeking Alpha
TD Cowen cuts Sarepta stock target, maintains Buy rating - Investing.com
Sarepta shares plummet as lower sales outlook adds to gloom over FDA’s new biologics hire - BioPharma Dive
Sarepta Therapeutics: Buy Rating Affirmed Amid Revenue Challenges and Strategic Adjustments - TipRanks
Sarepta (SRPT) Target Price Lowered by Needham Amid Leadership Change Concerns | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Reduced by Piper Sandler | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT): Analyst Lowers Price Target but Maintains Rating | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Target Price Revised by Cantor Fitzgerald | SRPT Stock News - GuruFocus
Sarepta (SRPT) Price Target Cut by RBC Capital Amid Elevidys Challenges | SRPT Stock News - GuruFocus
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga
Sarepta Therapeutics (SRPT) Sees Price Target Reduced by Analyst | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Lowered by Morgan Stanley | SRPT Stock News - GuruFocus
Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results - Benzinga
Sarepta Therapeutics (SRPT) Price Target Lowered by Needham Analyst | SRPT Stock News - GuruFocus
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2025 Earnings Call Transcript - Insider Monkey
Sarepta (SRPT) Faces Price Target Reduction Amid Revenue Challenges | SRPT Stock News - GuruFocus
Sarepta stock target cut to $40 by H.C. Wainwright on slow sales - Investing.com
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Sarepta (SRPT) Target Price Reduced Amid Regulatory Concerns | SRPT Stock News - GuruFocus
Sarepta tries to quell concerns over DMD gene therapy Elevidys as patients delay treatment after death report - Fierce Pharma
Sarepta Therapeutics: Buy Rating Affirmed Amidst Strong Growth and Strategic Resilience - TipRanks
Guggenheim Adjusts Sarepta (SRPT) Price Target Amid Uncertainty | SRPT Stock News - GuruFocus
S&P 500 Futures Rise in Premarket Trading; Sarepta Therapeutics, OneStream Lag - Barron's
Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales - Yahoo Finance
Sarepta (SRPT) Price Target Reduced by Morgan Stanley Amid Elevidys Sales Challenges | SRPT Stock News - GuruFocus
Sarepta (SRPT) Faces Target Price Cut Amid Revenue Miss and Regulatory Concerns | SRPT Stock News - GuruFocus
Sarepta (SRPT) Sees Reduced Price Target Amid Revenue and FDA Concerns | SRPT Stock News - GuruFocus
Sarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ... By GuruFocus - Investing.com Canada
Sarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ... - Yahoo Finance
Sarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst Challenges - GuruFocus
Sarepta Therapeutics (SRPT) Slashes 2025 Revenue Forecast, Shares Plunge - GuruFocus
Sarepta Therapeutics Reports Revenue Growth Amid Losses - TipRanks
Sarepta Therapeutics: Q1 Earnings Snapshot - CTPost
4.10%
자본화:
|
볼륨(24시간):